Semaglutide is one of the most discussed peptide-based medicines in recent memory, used in research and clinical settings to study obesity and type 2 diabetes. Right now it carries a price tag that puts it out of reach for most of the world. A new analysis published in the journal Obesity asks a straightforward question: once patents expire and generic manufacturers can step in, how low could the price actually go?
The answer, according to the researchers, is surprisingly low for injectable forms, though the oral version is a different story. The study also maps out which countries stand to gain access and how much of the global disease burden they carry, giving a clearer picture of what generic entry could mean at a population level.
This is a research and economics analysis, not a clinical recommendation. What it offers is a data-driven look at the relationship between production costs, patent law, and access to a compound that has attracted enormous scientific interest.
What the researchers set out to do
The study had two main goals. First, the team wanted to estimate realistic production costs for both injectable and oral forms of semaglutide using real supply chain data. Second, they wanted to quantify how much of the global obesity and type 2 diabetes burden sits in countries where generic versions might become available after patents begin to expire in 2026.
To do this, they pulled population data from the World Bank and disease prevalence estimates from the World Obesity and Diabetes Atlas. For production costs, they used active pharmaceutical ingredient shipment data from India collected between 2024 and 2025, then layered in assumptions about formulation, packaging, taxes, and a standard profit margin. This method is called cost-plus pricing and is commonly used in generic drug economics research.
The patent landscape
Patent status is the first gate between a branded compound and affordable generics. The researchers used a database called MedsPaL and cross-checked it against regional patent registries to map out where and when protections are set to lapse.
Their findings were notable. Twelve countries have patents expiring in 2026, and those twelve countries alone account for roughly 47 percent of global obesity and 49 percent of global type 2 diabetes cases. Beyond those twelve, the researchers found no patent filings at all in 150 additional countries. That means that by the end of 2026, generic injectable semaglutide could legally be manufactured and sold in approximately 162 countries. Those countries together represent about 69 percent of the global type 2 diabetes burden and 84 percent of clinical obesity cases worldwide.
In plain terms, the intellectual property barrier is lower than many observers assumed. A large share of the global disease burden lives in places where no one ever filed a patent in the first place.
Estimated production costs
Using the cost-plus method and the Indian API shipment data, the researchers calculated a range of plausible generic prices. For injectable semaglutide, the estimated cost came out to between $28 and $140 per person per year. That is a wide range, and the spread reflects different assumptions about manufacturing scale, profit margin, and supply chain efficiency.
Oral semaglutide is considerably more expensive to produce. The estimates for oral formulations ranged from $186 to $380 per person per year. The higher cost reflects the complexity of making a peptide survive the digestive system long enough to be absorbed, which requires specialized coating and absorption-enhancing agents that add to the manufacturing bill.
For context, current branded pricing in high-income markets runs into the thousands of dollars per year. Even the high end of the generic cost estimates represents a dramatic reduction.
The device problem
One finding that stands out in the analysis is the role of injection devices in total cost. The researchers noted that the autoinjector pen used to deliver injectable semaglutide contributes disproportionately to the overall per-patient price. The active peptide itself can be produced relatively cheaply at generic scale, but the delivery device adds a meaningful layer of cost that does not disappear with patent expiry.
This is a practical constraint that policy discussions about access often overlook. Even if the peptide ingredient becomes inexpensive, patients still need a functioning, safe, and accurate delivery system. The literature suggests that without targeted efforts to reduce device costs, or to develop simpler delivery alternatives, the theoretical savings from generic entry may not fully translate into real-world affordability.
Barriers that remain after patent expiry
The researchers are careful not to present generic entry as a complete solution. Three categories of barriers get particular attention in their analysis.
First, secondary patents. Pharmaceutical companies routinely file additional patents on things like specific formulations, delivery mechanisms, or manufacturing processes. These secondary patents can legally block generic entry even after the core compound patent lapses. The study notes this as a meaningful risk, particularly for oral formulations.
Second, health system constraints. Many of the 162 countries where generic access could become possible lack the supply chains, cold storage infrastructure, trained prescribers, or regulatory capacity to actually get a product from a manufacturer to a patient. Patent expiry creates a legal opening, but it does not build a health system.
Third, coordinated policy action. The researchers conclude that without deliberate intervention from governments, international health bodies, and procurement organizations, equitable uptake is unlikely to happen automatically. Price is necessary but not sufficient.
What this means for the research field
For researchers and scientists studying GLP-1 receptor agonist peptides, this analysis adds an important economic dimension to a field that has been largely focused on mechanisms and clinical outcomes. The data suggest that the compound itself is not inherently expensive to produce at scale. The cost drivers are formulation complexity, delivery devices, and the legal and regulatory infrastructure around them.
The study also reinforces why the injectable route has attracted so much research attention compared to oral administration. Lower production costs, simpler formulation, and a more predictable pharmacokinetic profile all favor the injectable form from a research and access standpoint.
Early data from this kind of health economics work points at a future where the cost of peptide-based metabolic research compounds could fall substantially, potentially enabling more research in lower-income settings that have historically been underrepresented in clinical trial populations. The literature suggests that closing that gap would improve the generalizability of trial results for populations that carry a disproportionate share of the global disease burden.
